Aptevo Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table summarizes the fees of Baker Tilly US, LLP, our Independent Registered Public Accounting firm, billed to us for their audit and other services for the years ended December 31, 2025 and 2024. The audit fees include an estimate of amounts not yet billed.
For the years ended December 31, 2025 and 2024, fees paid or accrued to Baker Tilly US, LLP were:
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Audit Fees | $504,738 | $455,000 |
| Audit-related Fees | - | - |
| Tax Fees | - | - |
| All Other Fees | - | - |
| Total Fees | $504,738 | $455,000 |
Audit Fees. Audit fees consist of fees from our principal auditor for the audit of our consolidated financial statements and other professional services provided in connection with statutory and regulatory filings or engagements and comfort letters.
Pre-Approval Policies and Procedures
The Audit Committee has policies and procedures that require the pre-approval by the Audit Committee (or one of its members) of all services performed by the Company’s independent registered public accounting firm and related fee arrangements. In the first half of each year, the Audit Committee approves the proposed services, including the nature, type and scope of services contemplated, and the related fees, to be rendered by these firms during the year. In accordance with this policy, the Audit Committee or one of its members pre-approved all services to be performed by the Company’s independent registered accounting firm.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.